about
A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.New RAF kinase inhibitors in cancer therapy.The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy.Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenograftsCurrent Development Status of MEK Inhibitors.FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial.Global Approaches to Understanding Protein Kinase Functions
P2860
Q37639582-0A50B3D4-5131-4E23-A48E-088D9D3AAB15Q38207082-50EEDC76-B4C8-4633-885A-BDE6842386D3Q38397326-563F79D2-5566-4364-990C-96D8E4832122Q42344756-5567A2DC-AB41-43E1-9ED3-F3A7048E6086Q47735535-682A2420-127D-456B-84D2-83194EB1A0D5Q50086506-00FDA1F7-C94A-43AD-8FBE-98D56CD98022Q57833109-BDBA14B3-8F7F-42CB-81E1-151A61F51550
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Prospects for MEK inhibitors for treating cancer.
@en
type
label
Prospects for MEK inhibitors for treating cancer.
@en
prefLabel
Prospects for MEK inhibitors for treating cancer.
@en
P2860
P1476
Prospects for MEK inhibitors for treating cancer
@en
P2093
James Larkin
Juan Martin-Liberal
P2860
P304
P356
10.1517/14740338.2014.892578
P407
P577
2014-03-06T00:00:00Z